Anakinra
IL-1 receptor antagonist
- Response rate
- ~90% (complete ~67%)
- Onset
- Hours–days
- Route
- SC 100mg daily (adults); 1–2 mg/kg/day (children)
- Line
- 1st
- IgM effect
- N/A
Evidence summary
IL-1 receptor antagonist that blocks both IL-1α and IL-1β signalling. Despite TRAPS being a TNF receptor disease, IL-1 blockade is the most effective treatment because the pathogenic cascade converges on IL-1β via mitochondrial ROS and NLRP3 activation. Eurofever data shows ~90% efficacy with ~67% complete remission. Can be used on-demand for milder cases or continuously for severe disease.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Key effector cytokine | Elevated | established |
Sources (4)
DetailsGattorno M et al. (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome · Arthritis RheumDOI ↗
DetailsGattorno M et al. (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis · Ann Rheum DisDOI ↗